Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer

Completed · Phase 1

Conditions studied: Neuroblastoma, Sarcoma

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody A1G4 plus BCG in treating patients with cancer.

Key facts

Study ID

NCT00003023

Run by

Memorial Sloan Kettering Cancer Center

People needed

24

Starts

1997-03-01

Last updated by the study team

2013-01-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.